Diagnosis and Treatment of Latent Tuberculosis Infection

Seung Heon Lee, M.D., Ph.D.
Division of Pulmonary, Sleep, and Critical Care Medicine, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea

A small number of viable tuberculosis bacilli can reside in an individual with latent tuberculosis infection (LTBI) without obvious clinical symptoms or abnormal chest radiographs. Diagnosis and treatment for LTBI are important for tuberculosis (TB) control in public and private health, especially in high-risk populations. The updated 2014 Korean guidelines for TB recommend that tuberculin skin tests, interferon-gamma release assays, or a combination of the two can be used for LTBI diagnosis according to age and immune status of the host as well as TB contact history. The regimens for LTBI treatment include isoniazid, rifampicin, or isoniazid/rifampicin. However, results of drug susceptibility test from the index case must be considered in selecting the appropriate drug for recent contacts. Standardized LTBI diagnosis and treatment based on the new 2014 guidelines will contribute to the effective TB control in Korea as well as to the establishment of updated guidelines.

Keywords: Latent Tuberculosis; Tuberculin Test; Interferon-Gamma Release Assay

Introduction

When humans are infected with Mycobacterium tuberculosis, tuberculosis (TB) only develops in 10% of those infected. TB develops in 5% of those infected, mostly within 1–2 years of M. tuberculosis infection.

Latent tuberculosis infection (LTBI) is the state in which human are infected with M. tuberculosis without any clinical symptoms, radiological abnormality, or microbiological evidence.

National Situation in Latent TB Infection

The TB burden of South Korea is intermediate, where the annual incidence of TB in 2013 was reported as 97/100,000. LTBI treatment was not emphasized until 2011, when Korean TB guidelines included aggressive LTBI treatment. Because of frequent TB outbreaks in schools and increasing number of immune-compromised patients including the elderly, guidelines for LTBI were enhanced in 2011 and updated in 2014. In this review, we will focus on the main points and revised contents of the 2014 Korean guidelines for TB.
LTBI Diagnosis Indication and Methods

1. Indication for LTBI diagnosis

LTBI diagnosis is based on the targeted TST strategy, which recommends a test for the subjects who have risk factors for developing active TB from LTBI. In the case of suspicious new infection for subjects who had been treated for LTBI or active TB, LTBI treatment can be done considering the risk of active TB progression.

2. Diagnosis for LTBI

For LTBI diagnosis, exclusion of active TB is essential, and the old healed TB without TB treatment history among the bellowed risk groups for TB development is considered as LTBI, even without an LTBI test. A TST test using RT-23 2TU and an interferon-gamma release assay (IGRA) test are used to diagnose LTBI. There are commercial IGRA tests such as QuantiFERON-TB Gold In Tube (QFT-IT; Qiagen, Valencia, CA, USA) and T-SPOT.TB (Oxford Immunotec, Abingdon, UK). However, these diagnostic tools do not differentiate LTBI from active TB infection.

1) LTBI diagnostic approach in immune-competent subjects: TST is the basic method to diagnose LTBI in immune-competent subjects, but IGRA alone can be used. Furthermore, a TST/IGRA two-step strategy in which the initial TST is followed by confirmatory IGRA for TST positive subjects can be used, because false positivity due to BCG vaccination or nontuberculous mycobacteria (NTM) infection can be reduced by additional IGRA test with high specificity. The diagnostic approach algorithm is presented in Figure 1.

2) LTBI diagnostic approach in immune-compromised subjects: IGRA alone or TST combined with IGRA can be used, but exclusion of LTBI using TST-negative result alone is not recommended. Either TST-positive or IGRA positive is regarded as LTBI in TST/IGRA combined method. The TST/IGRA two-step strategy is not recommended in immune-compromised subjects in contrast to immune-competent subjects. Old spontaneously healed TB lesion without TB treatment history is regarded as LTBI, even when the LTBI test is negative. An indeterminate result on the initial IGRA test in immune-compromised subjects is frequently repeated on subsequent IGRA test, so LTBI confirmation can be made based on TST result. The diagnostic approach algorithm is presented in Figure 2.

3. Serial TST and IGRA

1) Serial TST: A serial test refers to a TST test following an initial TST in contact investigation to exclude a false-negative
result during the period of 8 weeks after the last contact with an infectious TB patient (window period); this is when the TST does not lead to complete response due to delayed hypersensitivity\textsuperscript{19}. On the other hand, a two-step TST, which is usually conducted for healthcare workers, means subsequent TST 1–4 weeks after the initial TST\textsuperscript{20}. This is because delayed response triggered by initial TST can appear due to recall immune phenomenon, in the subjects who are previously infected with latent TB (booster effect)\textsuperscript{19}. In the subjects whose basal initial TST result is negative, TST conversion (from negative to positive) after several months can strongly suggest a new TB infection\textsuperscript{19}.

Serial TST is recommended in high/moderate risk groups (Table 1) and children ≤18 years of age. In the subjects with TST <5 mm, TST conversion is confirmed with a subsequent TST ≥6 mm\textsuperscript{19}. This rule applies to regular follow-up checks for healthcare workers. But in contact investigation, a TST increase of ≥6 mm from the initial TST result (e.g., 3 mm to 9 mm) indicates conversion under the following conditions: highly infectious index case, close TB contacts, long duration of contact, contacts <5 years, or immune-compromised contacts\textsuperscript{19}.

2) **IGRA in children and adolescents**: IGRA is not recommended in children <5 years of age\textsuperscript{21}. An IGRA test alone is not recommended for the subjects of 5–18 years of age\textsuperscript{21,22}, except under the conditions in which TST result is highly likely to be a false-positive—a BCG vaccination after 1 year or BCG revaccination\textsuperscript{22,23}.

**Indications for LTBI Treatment**

LTBI diagnosis is based upon the premise that the subjects with a positive LTBI test must be treated. The candidates for LTBI diagnosis is categorized into two groups: those with contact with infectious TB patients and those without contact with infectious TB patients.

1. **Non-contacts with infectious TB patients**

   The candidates for LTBI diagnosis can be classified as high risk groups and moderate risk groups\textsuperscript{22}. For the subjects with LTBI-positive in the high risk group, LTBI treatment must be conducted; but for those with LTBI-positive in the moderate risk group, LTBI treatment can be considered (Table 1). In 2014 Korean new guideline, head and neck cancer and hematologic malignancy were included in the moderate risk group\textsuperscript{24}.

2. **Contacts with infectious TB patients**

   In contact investigation condition, candidates for LTBI screening is restricted to those who are ≤35 years old, because risk owing to hepatotoxicity by anti-TB drugs exceed the benefit of LTBI treatment. For those who are ≤35 years old with LTBI-positive, LTBI treatment is obligatory\textsuperscript{17}. For LTBI-positive subjects in the above mentioned high/moderate risk groups, LTBI treatment is necessary for those that had contact with an infectious TB patient (Table 2). The patients with head and neck cancer or hematologic malignancy were added for this group in the 2014 Korean guidelines.

   A serial repeated TST must be performed for people in the high/moderate risk group, who had an initial negative TST result after 8 weeks since their last contact with an infectious TB patients\textsuperscript{25}. LTBI treatment must be maintained during the window period even though the initial TST result was negative for contacts <2 years old\textsuperscript{17}, those on immunosuppressive agents who received a transplant, or those on tumor necrosis factor (TNF) α blockers.

   Based on the repeated TST result after 8 weeks of window period, LTBI treatment must be continued for the contact with a positive result, but LTBI treatment can be stopped for those who
with a negative result. However, for the human immunodeficiency virus–positive, LTBI treatment must be continued even after a repeated TST-negative result. For the contacts with initial TST-negative result in the moderate risk group, the decision for LTBI treatment must be delayed until a repeated TST is taken after 8 weeks of window period. The risk groups are as follows: between 2–18 years of age; taking long-term steroids or scheduled to take long-term steroids; having silicosis, end stage renal failure, diabetes mellitus, head and neck cancer, or hematologic malignancy; and gastrectomy/jejunoileal bypass or scheduled for one. For contacts with TST conversion (from TST-negative to TST-positive), LTBI treatment must be performed; but for people without TST conversion (from TST-negative to TST-negative), LTBI treatment is unnecessary.

**LTBI Treatment**

The drug susceptibility test (DST) from the index case must be considered when selecting the appropriated drug for recent TB contacts, and the LTBI treatments are as follows.

**1. Regimens for LTBI treatment**

1) **Isoniazid mono treatment:** Isoniazid (5 mg/kg/day, maximum 300 mg/day) for 9 months (9H) is recommended, but isoniazid for 6 months (6H) can be reasonable considering the cost-effectiveness.

2) Short course treatment regimens containing rifampicin:
   (1) **Rifampicin mono treatment:** Rifampicin treatment for 4 months (4R) has excellent treatment completion rate, and this regimen can be given to the contacts exposed to an index case with a strain resistant to isoniazid.
   (2) **Isoniazid/rifampicin combination regimen:** Isoniazid/rifampicin combination regimen for 3 month (3HR) is recommended by the National Institutes for Health and Clinical Excellence (NICE) guideline. This regimen has excellent...
treatment compliance rate\(^28\) and was reported to be superior to 9H regimen in treatment efficacy\(^29\). Moreover, isoniazid / rifapentine combination regimen (once a week for 12 weeks) was recently introduced as a new regimen\(^30\), but rifapentine is not available yet in Korea.

2. Monitoring during the LTBI treatment

Basal complete blood count, aspartate aminotransferase/alanine aminotransferase, and bilirubin must be checked before LTBI treatment. A liver function test must be checked monthly for the subjects with basal abnormal liver function test results or with risk factors. There is no method to verify complete eradication of LTBI, so TST or IGRA result does not verify complete LTBI treatment.

3. LTBI treatment in special condition

1) Pregnancy: The 9H regimen is recommended, and pyridoxine must be supplied to infant whose mother is being treated with isoniazid for LTBI. The 4R regimen can be given to pregnant women, but further investigation is needed for this regimen.

2) Contacts who contacted with the multi-drug resistant TB: Generally, LTBI treatment is not recommended due to lack of data, and follow-up for 2 years is recommended\(^30\).

4. Retreatment for LTBI

Retreatment for LTBI is considered for people in high/moderate risk groups, who had recent contact, even though they have completed LTBI treatment.

5. Treatment for active TB developed during LTBI treatment

First line standard regimen containing already prescribed drugs for LTBI treatment is recommended.

LTBI Diagnosis and Treatment in TNF Blockers Users

1. LTBI diagnosis for subjects who will use TNF blockers

The guidelines for LTBI diagnosis for these subjects is same for the guidelines for immune-compromised patients. IGRA alone or TST/IGRA combination tests can be used, but LTBI diagnosis with TST alone is not recommended. In TST/IGRA combination tests, LTBI can be confirmed by either TST-positive or IGRA-positive\(^41\). A TST-positive criterion is induration size ≥10 mm. Two-step TST can be considered, if applicable, to increase the sensitivity of LTBI diagnosis in immune-compromised subjects\(^42\).
2. LTBI treatment and active TB treatment for subjects who will use TNF blockers

Active TB detected by basal examination must be treated, and TNF blockers are recommended to be started after the completion of active TB treatment. But, TNF blockers can be started after 2 months of intensive treatment for active TB\(^1\), under the following conditions: the disease is not severe, responses to anti TB drugs are favorable, and the strain is drug-susceptible. LTBI detected by basal examination must be treated. TNF blockers are recommended to be started 3 weeks after the initial LTBI treatment\(^2\), but TNF blockers treatment and LTBI treatment may be initiated at the same time\(^3\).

3. Monitoring for TB during TNF blocker treatment

Prompt examination reacting to the symptoms suggesting TB is preferred to regular chest radiographs screening for TB development. The incidences of extrapulmonary tuberculosis, NTM disease, or severe TB are high during the uses of TNF blockers, so particular attention must be paid.

LTBI Diagnosis and Treatment in Patients with Organ Transplants

The examinations for active TB and LTBI must be performed for patients with organ transplants, who are taking or will be taking immunosuppressive agents. LTBI diagnosis comply with the guidelines for immune-compromised subjects. LTBI screening is preferably recommended before immunosuppressive agents are begun, to decrease the indeterminate result of IGRA.

In a Korean study where TST and T-SPOT TB tests for LTBI diagnosis and treatment were performed for 312 patients with kidney transplants, T-SPOT TB tests for the patients with TST-negative results were useful in predicting active TB development\(^4\). Based on either TST-positive or IGRA-positive after excluding active TB, LTBI is confirmed because the concordance rate is not so high between TST and IGRA for the patients waiting for kidney transplants\(^5,6\). In the same context, TST-positive or IGRA-positive can confirm the LTBI after excluding active TB in the subjects with organ transplants or waiting for organ transplants. The 9H regimen for LTBI treatment is recommended, but 4R or 3HR can be considered to complete the LTBI treatment before transplantation.

Conclusions

The followings are modifications in the 2014 Korean guidelines for TB, from the 2011 guidelines. Head and neck cancer and hematologic malignancy were added to the risk group for LTBI diagnosis and treatment. For non-contacts with infectious TB patients, the candidates for LTBI diagnosis and treatment were classified into a high risk group and moderate risk group. For LTBI treatment, the results of the DST from the index case must be considered in selecting the appropriate drug for recent TB contacts. The guidelines expressing IGRA’s important role for the patients with organ transplants were added. In immune-compromised patients including TNF blocker users, LTBI can be diagnosed with either TST-positive or IGRA-positive, but cannot be excluded with TST-negative alone. In the public sector, LTBI screening for contacts to infectious TB patients are actively progressing with government-centered policy. In the private sector, clinicians are faced with the need to actively treat growing number of immune-compromised patients with LTBI, including the patients with organ transplants and those taking immunosuppressive agents. Conclusively, the 2014 Korean guidelines for TB, based on standardized LTBI diagnosis and treatment, is expected to be upgraded in the near future, supplementing the LTBI guidelines for growing foreign residents in an era of internationalization.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976;19:1-63.
2. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003;362:887-99.
3. World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization; 2014.
4. Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korean Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. Seoul: Korean Centers for Disease Control and Prevention; 2011.
5. Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korean Centers for Disease Control and Prevention. Korean guidelines for tuberculosis, 2nd ed. Seoul and Cheongwon: Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention; 2014.
6. Hong YP, Kim SJ, Lev WJ, Lee EK, Han YC. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis 1998;2:27-36.
7. Choi CM, Kang CI, Kim DH, Kim CH, Kim HJ, Lee CH, et al. The role of TST in the diagnosis of latent tuberculosis infec-
tion among military personnel in South Korea. Int J Tuberc Lung Dis 2006;10:1342–6.
8. Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006;28:24–30.
9. Lee SW, Oh SY, Lee JB, Choi CM, Kim HJ. Tuberculin skin test distribution following a change in BCG vaccination policy. PLoS One 2014;9:e86419.
10. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161(4 Pt 2):S221–47.
11. Grzybowski S, Fishhaut H, Rowe J, Brown A. Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service. Am Rev Respir Dis 1971;104:605–8.
12. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America. (IDSA), September 1999. Am J Respir Crit Care Med 2000;161(4 Pt 1):1376–95.
13. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293:2756–61.
14. Song S, Jeon D, Kim JW, Kim YD, Kim SP, Cho JS, et al. Performance of confirmatory interferon-gamma release assays in school TB outbreaks. Chest 2012;141:598–6.
15. Kim HJ, Lee GH, Ryoo S, Oh SY, Lee JB, Kim JH, et al. Role of confirmatory interferon-gamma release assays in school outbreaks of tuberculosis in South Korea. Int J Tuberc Lung Dis Forthcoming 2015.
16. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185–206.
17. National Institute for Health and Care Excellence. Clinical guideline 33. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control [Internet]. London: National Institute for Health and Care Excellence; 2011 [cited 2014 Dec 12]. Available from: http://www.nice.org.uk/CG117.
18. Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am J Respir Crit Care Med 2013;187:206–11.
19. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15–21.
20. Kim SY, Park MS, Kim YS, Kim SK, Chang J, Yong D, et al. Tuberculin skin test and boosted reactions among newly employed healthcare workers: an observational study. PLoS One 2013;8:e64563.
21. World Health Organization. Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. 2nd ed. Geneva: World Health Organization; 2014.
22. Canadian Thoracic Society. The Public Health Agency of Canada and Licensors. Canadian tuberculosis standards. 7th ed. Ottawa: Public Health Agency of Canada; 2014.
23. American Academy of Pediatrics. Tuberculosis. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, editors. Red Book: 2012 Report of the Committee on Infectious Disease. Elk Grove Village, IL: American Academy of Pediatrics; 2012. p. 736–59.
24. Masurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection: United States, 2010. MMWR Recomm Rep 2010;59:1–25.
25. National Tuberculosis Controllers Association; Centers for Disease Control and Prevention (CDC). Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 2005;54:1–47.
26. Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology 2010;15:603–22.
27. Lee SH, Yim JJ, Kim HJ, Shim TS, Seo HS, Cho YS, et al. Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak. Epidemiol Infect 2012;140:1028–35.
28. Yun JW, Lim SY, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci 2007;22:779–83.
29. Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715–22.
30. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155–66.
31. Jung YJ, Lee JY, Jo KW, Yoo B, Lee CK, Kim YG, et al. The ‘either test positive’ strategy for latent tuberculosis infection before anti-tumour necrosis factor treatment. Int J Tuberc Lung Dis 2014;18:428–34.
32. Gomez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61.

33. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5.

34. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003;62:791.

35. Shim TS. Diagnosis and treatment of latent tuberculosis infection due to initiation of anti-TNF therapy. Tuberc Respir Dis 2014;76:261-8.

36. Kim SH, Lee SO, Park JB, Park IA, Park SJ, Yun SC, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am J Transplant 2011;11:1927-35.

37. Kim SY, Jung GS, Kim SK, Chang J, Kim MS, Kim YS, et al. Comparison of the tuberculin skin test and interferon-gamma release assay for the diagnosis of latent tuberculosis infection before kidney transplantation. Infection 2013;41:103-10.

38. Kim SH, Lee SO, Park IA, Park SJ, Choi SH, Kim YS, et al. Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation. Transpl Infect Dis 2010;12:113-9.